Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Circumcision, Male | 9 | 2024 | 99 | 3.290 |
Why?
|
| Tuberculosis | 21 | 2025 | 543 | 2.870 |
Why?
|
| Chronic Disease | 5 | 2020 | 107 | 2.770 |
Why?
|
| HIV Infections | 34 | 2024 | 5097 | 1.990 |
Why?
|
| South Africa | 69 | 2025 | 7596 | 1.950 |
Why?
|
| Humans | 78 | 2025 | 14537 | 1.700 |
Why?
|
| Tuberculosis, Pulmonary | 9 | 2023 | 324 | 1.680 |
Why?
|
| Ambulatory Care Facilities | 6 | 2022 | 125 | 1.560 |
Why?
|
| Male | 46 | 2024 | 6754 | 1.500 |
Why?
|
| Disease Management | 3 | 2020 | 74 | 1.490 |
Why?
|
| Adult | 44 | 2024 | 5913 | 1.410 |
Why?
|
| Funeral Homes | 2 | 2019 | 6 | 1.300 |
Why?
|
| Contact Tracing | 7 | 2023 | 48 | 1.270 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2023 | 256 | 1.270 |
Why?
|
| Cross-Sectional Studies | 21 | 2023 | 1422 | 1.200 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2023 | 329 | 1.110 |
Why?
|
| Mass Screening | 6 | 2023 | 245 | 1.050 |
Why?
|
| Pre-Exposure Prophylaxis | 6 | 2024 | 196 | 1.010 |
Why?
|
| Communicable Disease Control | 4 | 2023 | 101 | 0.930 |
Why?
|
| Young Adult | 19 | 2024 | 2498 | 0.850 |
Why?
|
| Female | 32 | 2024 | 9103 | 0.840 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 33 | 0.840 |
Why?
|
| Latent Tuberculosis | 3 | 2020 | 45 | 0.810 |
Why?
|
| Surgical Instruments | 3 | 2019 | 11 | 0.800 |
Why?
|
| Penis | 2 | 2019 | 8 | 0.790 |
Why?
|
| Disease Notification | 2 | 2025 | 14 | 0.780 |
Why?
|
| Organizational Culture | 1 | 2020 | 7 | 0.710 |
Why?
|
| Models, Economic | 1 | 2020 | 15 | 0.700 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 42 | 0.690 |
Why?
|
| Middle Aged | 20 | 2024 | 3601 | 0.690 |
Why?
|
| Prospective Studies | 14 | 2024 | 1160 | 0.680 |
Why?
|
| Health Personnel | 4 | 2019 | 231 | 0.670 |
Why?
|
| Medical Waste Disposal | 1 | 2019 | 3 | 0.670 |
Why?
|
| Safety Management | 1 | 2019 | 4 | 0.670 |
Why?
|
| Amputation, Traumatic | 1 | 2019 | 2 | 0.670 |
Why?
|
| Antitubercular Agents | 3 | 2021 | 322 | 0.660 |
Why?
|
| Personal Protective Equipment | 1 | 2019 | 16 | 0.660 |
Why?
|
| Self Care | 1 | 2019 | 14 | 0.660 |
Why?
|
| Postoperative Complications | 1 | 2019 | 34 | 0.660 |
Why?
|
| Serologic Tests | 1 | 2019 | 26 | 0.650 |
Why?
|
| Child | 15 | 2024 | 2242 | 0.650 |
Why?
|
| Pain | 2 | 2018 | 41 | 0.650 |
Why?
|
| Health Care Costs | 2 | 2019 | 115 | 0.650 |
Why?
|
| Adolescent | 16 | 2024 | 2985 | 0.640 |
Why?
|
| Mortuary Practice | 1 | 2019 | 3 | 0.640 |
Why?
|
| Occupational Diseases | 1 | 2019 | 40 | 0.610 |
Why?
|
| Research | 1 | 2019 | 65 | 0.610 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 1324 | 0.610 |
Why?
|
| Isoniazid | 2 | 2020 | 110 | 0.600 |
Why?
|
| Influenza, Human | 4 | 2023 | 374 | 0.560 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 239 | 0.550 |
Why?
|
| Treatment Refusal | 1 | 2016 | 13 | 0.530 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2021 | 195 | 0.520 |
Why?
|
| HIV Seropositivity | 3 | 2023 | 265 | 0.510 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 200 | 0.510 |
Why?
|
| Inservice Training | 1 | 2015 | 7 | 0.500 |
Why?
|
| Allied Health Personnel | 1 | 2015 | 6 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 262 | 0.490 |
Why?
|
| Politics | 1 | 2015 | 24 | 0.490 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 54 | 0.480 |
Why?
|
| Rural Health Services | 1 | 2015 | 48 | 0.480 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 132 | 0.480 |
Why?
|
| HIV | 6 | 2023 | 380 | 0.450 |
Why?
|
| Primary Health Care | 5 | 2023 | 240 | 0.430 |
Why?
|
| Sputum | 4 | 2023 | 135 | 0.430 |
Why?
|
| Floxacillin | 1 | 2013 | 6 | 0.430 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 13 | 0.430 |
Why?
|
| Foreskin | 3 | 2024 | 12 | 0.430 |
Why?
|
| Epidemics | 2 | 2024 | 65 | 0.420 |
Why?
|
| Child, Preschool | 7 | 2024 | 1748 | 0.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2024 | 155 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 293 | 0.360 |
Why?
|
| Models, Organizational | 2 | 2020 | 3 | 0.340 |
Why?
|
| Prevalence | 7 | 2023 | 1192 | 0.330 |
Why?
|
| Health Expenditures | 2 | 2019 | 39 | 0.320 |
Why?
|
| Aged | 7 | 2023 | 1740 | 0.310 |
Why?
|
| Infant | 6 | 2024 | 2244 | 0.260 |
Why?
|
| Emtricitabine | 2 | 2023 | 78 | 0.250 |
Why?
|
| Incidence | 5 | 2024 | 685 | 0.250 |
Why?
|
| Tuberculin Test | 4 | 2020 | 49 | 0.250 |
Why?
|
| Smoking Cessation | 1 | 2024 | 9 | 0.240 |
Why?
|
| Tight Junctions | 1 | 2024 | 2 | 0.240 |
Why?
|
| Rural Population | 4 | 2021 | 654 | 0.230 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 60 | 0.230 |
Why?
|
| Cohort Studies | 6 | 2024 | 967 | 0.230 |
Why?
|
| Treatment Outcome | 4 | 2024 | 889 | 0.220 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 101 | 0.220 |
Why?
|
| Sexual Health | 1 | 2023 | 14 | 0.220 |
Why?
|
| Intention | 1 | 2023 | 23 | 0.220 |
Why?
|
| Nicotine | 1 | 2023 | 12 | 0.210 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 7 | 0.210 |
Why?
|
| Cannabis | 1 | 2022 | 10 | 0.210 |
Why?
|
| Tobacco Smoking | 2 | 2022 | 15 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2024 | 656 | 0.210 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 29 | 0.210 |
Why?
|
| Motivation | 1 | 2023 | 59 | 0.210 |
Why?
|
| Chemokine CCL4 | 1 | 2022 | 14 | 0.200 |
Why?
|
| Whooping Cough | 1 | 2023 | 36 | 0.200 |
Why?
|
| Family Characteristics | 5 | 2022 | 135 | 0.190 |
Why?
|
| Risk Factors | 6 | 2022 | 1475 | 0.190 |
Why?
|
| Bacterial Load | 1 | 2021 | 32 | 0.190 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 34 | 0.190 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.180 |
Why?
|
| Telemedicine | 1 | 2021 | 25 | 0.180 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 21 | 0.180 |
Why?
|
| Rural Health | 1 | 2021 | 118 | 0.180 |
Why?
|
| Cell Phone | 1 | 2020 | 34 | 0.180 |
Why?
|
| HIV-1 | 3 | 2024 | 1260 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 103 | 0.170 |
Why?
|
| Health Care Surveys | 1 | 2019 | 30 | 0.170 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 7 | 0.170 |
Why?
|
| Waste Disposal Facilities | 1 | 2019 | 9 | 0.170 |
Why?
|
| Workload | 1 | 2019 | 13 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 299 | 0.160 |
Why?
|
| Tobacco Use | 1 | 2019 | 12 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 39 | 0.160 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 26 | 0.160 |
Why?
|
| Program Development | 1 | 2019 | 32 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2019 | 101 | 0.160 |
Why?
|
| Research Personnel | 1 | 2019 | 19 | 0.160 |
Why?
|
| Virus Shedding | 1 | 2018 | 24 | 0.160 |
Why?
|
| Coinfection | 2 | 2020 | 276 | 0.150 |
Why?
|
| Poverty | 1 | 2019 | 152 | 0.150 |
Why?
|
| Orthomyxoviridae | 1 | 2018 | 33 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2020 | 151 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 8 | 0.150 |
Why?
|
| Analgesia | 1 | 2018 | 8 | 0.150 |
Why?
|
| Pain Management | 1 | 2018 | 12 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 188 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2020 | 1479 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2019 | 167 | 0.150 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2017 | 5 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2018 | 56 | 0.150 |
Why?
|
| Seroepidemiologic Studies | 3 | 2023 | 109 | 0.150 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 563 | 0.150 |
Why?
|
| Air Pollution, Indoor | 1 | 2017 | 13 | 0.150 |
Why?
|
| Sex Workers | 1 | 2019 | 116 | 0.150 |
Why?
|
| Pleural Cavity | 1 | 2017 | 7 | 0.140 |
Why?
|
| Vaccination | 1 | 2019 | 365 | 0.140 |
Why?
|
| Radiography | 1 | 2017 | 80 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 106 | 0.140 |
Why?
|
| Genital Diseases, Male | 1 | 2016 | 8 | 0.130 |
Why?
|
| Perception | 1 | 2016 | 42 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2015 | 15 | 0.130 |
Why?
|
| Lung | 1 | 2015 | 70 | 0.120 |
Why?
|
| Quality Control | 1 | 2015 | 27 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 14 | 0.120 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 13 | 0.120 |
Why?
|
| Schools | 1 | 2015 | 73 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2019 | 799 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 217 | 0.120 |
Why?
|
| Product Packaging | 1 | 2014 | 2 | 0.120 |
Why?
|
| Crime | 1 | 2014 | 3 | 0.120 |
Why?
|
| Tobacco Products | 1 | 2014 | 8 | 0.120 |
Why?
|
| Commerce | 1 | 2014 | 22 | 0.110 |
Why?
|
| Time Factors | 1 | 2015 | 507 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2013 | 127 | 0.100 |
Why?
|
| Uganda | 2 | 2024 | 197 | 0.100 |
Why?
|
| Seasons | 2 | 2023 | 154 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 253 | 0.100 |
Why?
|
| Linear Models | 2 | 2023 | 83 | 0.100 |
Why?
|
| Viral Load | 3 | 2020 | 819 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.090 |
Why?
|
| Autopsy | 2 | 2023 | 140 | 0.080 |
Why?
|
| Cotinine | 1 | 2024 | 7 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2025 | 55 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 48 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2024 | 64 | 0.060 |
Why?
|
| Mucous Membrane | 1 | 2023 | 12 | 0.060 |
Why?
|
| Phylogeny | 1 | 2024 | 231 | 0.060 |
Why?
|
| Counseling | 1 | 2024 | 143 | 0.060 |
Why?
|
| Cough | 1 | 2023 | 14 | 0.060 |
Why?
|
| Tenofovir | 1 | 2024 | 171 | 0.050 |
Why?
|
| Claudin-1 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2024 | 175 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 103 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2022 | 2 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 2 | 0.050 |
Why?
|
| Ion Channels | 1 | 2022 | 3 | 0.050 |
Why?
|
| Mutation | 1 | 2024 | 306 | 0.050 |
Why?
|
| Bordetella pertussis | 1 | 2023 | 29 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Chemokine CCL3 | 1 | 2022 | 23 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 52 | 0.050 |
Why?
|
| Smoking | 1 | 2023 | 100 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 435 | 0.050 |
Why?
|
| Carrier State | 1 | 2023 | 92 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2023 | 151 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 385 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 82 | 0.050 |
Why?
|
| Microscopy | 1 | 2021 | 21 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 303 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 47 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 59 | 0.040 |
Why?
|
| Obesity | 1 | 2024 | 367 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2020 | 120 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 370 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 336 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 47 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 278 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2021 | 215 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 244 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 30 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 87 | 0.040 |
Why?
|
| Income | 1 | 2019 | 85 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 65 | 0.040 |
Why?
|
| Urban Population | 1 | 2021 | 257 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 114 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 89 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 3 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 23 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2018 | 49 | 0.040 |
Why?
|
| Kerosene | 1 | 2017 | 4 | 0.040 |
Why?
|
| Comorbidity | 1 | 2018 | 188 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 468 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 7 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 411 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2018 | 203 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2017 | 45 | 0.040 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 47 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 154 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2015 | 3 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 321 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cities | 1 | 2014 | 37 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 472 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 179 | 0.030 |
Why?
|